myNEO Therapeutics
Cedric Bogaert is a Co-Founder and CEO at myNEO Therapeutics since January 2019, a biopharmaceutical company focused on developing innovative immunotherapies to combat cancer. Cedric is also a Co-Founder at Persomed life sciences since January 2020, working on personalized neoantigen-driven DC vaccines for colorectal cancer patients. Previously, Cedric worked as a Business&Integration Arch Senior Analyst at Accenture from January 2018 to January 2019. With a background in Bio Engineering and a strong focus on genetics, Cedric is known for their expertise in developing immunovaccines and utilizing innovative technology in the field.
This person is not in any teams
myNEO Therapeutics
myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond. In parallel, the service angle of myNEO Therapeutics, myNEO Intelligence, assists biopharma companies in transforming their decision-making process from trial & error to data-driven decisions using an AI-powered platform. Deriving insights from its expansive library of clinical and molecular data, myNEO Intelligence maps the molecular profiling of cancer patients at an individual level and then correlates the different data points to make data-driven decisions across the drug development life cycle. myNEO Intelligence can identify novel targets and biomarkers, prioritize drug candidates and indications, stratify patient populations and predict treatment response.